Basilea reports total revenue exceeding guidance driven by higher than expected contributions from Cresemba® and Zevtera® in 2019

NEXT STORY
Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
PREV STORY
AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

author_avatar
NASDAQ Market News

EBS DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP – Important June 18, 2021 Deadline Reminder for Emergent BioSolutions Inc. Investors

author_avatar
NASDAQ Market News

Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis

author_avatar
NASDAQ Market News